Invasive Micropapillary Breast Carcinoma

DSpace Repository

Show simple item record

dc.contributor.advisor Fend, Falko (Prof. Dr.)
dc.contributor.author Warzecha, Hind
dc.date.accessioned 2018-09-04T13:38:26Z
dc.date.available 2018-09-04T13:38:26Z
dc.date.issued 2018-09-04
dc.identifier.other 510716482 de_DE
dc.identifier.uri http://hdl.handle.net/10900/84125
dc.identifier.uri http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-841255 de_DE
dc.identifier.uri http://dx.doi.org/10.15496/publikation-25515
dc.description.abstract Invasive micropapillary morphology is associated with clinically meaningful staging and outcome implications in patients with breast cancer. The characteristic micropapillary morphology is seen focally in the tumor in most cases. In contrast to other special subtypes of breast cancer, any proportion of invasive micropapillary growth confers to the tumor a “special” aggressive behaviour characterised by lymphovascular invasion, high propensity for lymph node metastases and high stage at presentation. At the molecular and immunohistochemical level, tumors with mixed invasive micropapillary and invasive carcinoma NST display striking similarities to those with pure invasive micropapillary carcinomas. Moreover, these tumors are classified in most cases in the category of luminal B molecular subtype. Invasive micropapillary carcinoma has been described in other organ systems, although less frequently as in breast. In the urinary tract, gastrointestinal tract, lungs and salivary glands, this tumor pattern is in general admixed with a more conventional tumor growth pattern, and same as in breast, presents as a locally advanced disease and is associated with an aggressive behaviour. To date there are few molecular studies performed on IMPCa of the breast. None of them shows characteristic genetic alteration that could explain the special morphology of the tumor or its aggressive course. In other terms, IMPCa is not defined by highly recurrent specific mutations or fusion genes. In few cases reported in the literature as well as in the study that we presented, hotspot point mutations of the PIK3CA gene, and the TP53 gene were identified however at a rate similar to that seen in invasive breast carcinoma NST. In addition we saw in one of our IMPCa cases a MET-T1010I germline mutation, which is usually very rare in breast cancer, occurring in 2% of patients with metastatic breast carcinoma. Because of the therapeutic consequences (with MET inhibitors) we suggest a more extensive testing of the MET gene in this aggressive type of breast cancer. en
dc.language.iso en de_DE
dc.publisher Universität Tübingen de_DE
dc.rights ubt-podok de_DE
dc.rights.uri http://tobias-lib.uni-tuebingen.de/doku/lic_mit_pod.php?la=de de_DE
dc.rights.uri http://tobias-lib.uni-tuebingen.de/doku/lic_mit_pod.php?la=en en
dc.subject.classification Krebs <Medizin> , Brustkrebs de_DE
dc.subject.ddc 610 de_DE
dc.subject.other Mammacarcinom de_DE
dc.subject.other Invasive breast cancer en
dc.subject.other Micropapillary en
dc.title Invasive Micropapillary Breast Carcinoma en
dc.type PhDThesis de_DE
dcterms.dateAccepted 2018-07-10
utue.publikation.fachbereich Medizin de_DE
utue.publikation.fakultaet 4 Medizinische Fakultät de_DE

Dateien:

This item appears in the following Collection(s)

Show simple item record